Skip to main content

Cellular Bio Acquires Rights to Solid Tumor Immunotherapy from National Cancer Institute

Cellular Biomedicine has been granted a Patent License for a next-gen neoantigen-reactive tumor infiltrating lymphocyte (TIL) technology from the National Cancer Institute of the US. The License gives CBMG non-exclusive, sub-licensable global rights to develop, manufacture and commercialize TIL technology. Financial details were not disclosed, nor did CMBG explain why the technology is "next-gen."  Headquartered in Silicon Valley, CBMG has operations in Shanghai and Beijing , where it develops immunotherapies for cancer and stem cell treatments for degenerative diseases. More details... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.